Oct 16, 2023 / 12:00PM GMT
Operator
Good day, everyone, and welcome to Pfizer's Analyst and Investor Call to review amended U.S. government PAXLOVID Supply Agreement and updated full year 2023 guidance.
Today's call is being recorded. At this time, I would like to turn the call over to Francesca DeMartino, Chief Investor Relations Officer and Senior Vice President. Please go ahead, ma'am.
Francesca DeMartino - Pfizer Inc. - Chief Investor Relations Officer & Senior VP
Good morning, and welcome to our call to review Pfizer's amended U.S. government PAXLOVID supply agreement and updated full year 2023 guidance. I'm Francesca DeMartino, Pfizer's Chief Investor Relations Officer. On behalf of the Pfizer team, thank you for joining us. This call is being made available via audio webcast at pfizer.com.
The news and guidance update that we will be discussing today was issued in a press release last Friday, which is available on our website at pfizer.com.
Leading today's call are Dr. Albert Bourla, our Chairman and CEO; and Dave Denton, our CFO. Albert and Dave have some
Pfizer Inc To Host Investment Analysts Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot